(Q50867754)

24 March 2018

title

Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. (English)

1 reference

24 March 2018

0 references

0 references

0 references

Sophie Lotersztajn

8

0 references

author name string

Adrien Guillot

1

1 reference

24 March 2018

Nabila Hamdaoui

2

1 reference

24 March 2018

Alexandra Bizy

3

1 reference

24 March 2018

Keve Zoltani

4

1 reference

24 March 2018

Rachid Souktani

5

1 reference

24 March 2018

Elie-Serge Zafrani

6

1 reference

24 March 2018

Ariane Mallat

7

1 reference

24 March 2018

Fouad Lafdil

9

1 reference

24 March 2018

language of work or name

English

0 references

publication date

19 November 2013

1 reference

24 March 2018

published in

Hepatology

1 reference

24 March 2018

volume

59

1 reference

24 March 2018

issue

1

1 reference

24 March 2018

page(s)

296-306

1 reference

24 March 2018

Mechanisms of hepatic fibrogenesis

cites work

1 reference

Immune interactions in hepatic fibrosis.

21 January 2018

1 reference

Hepatic fibrosis: molecular mechanisms and drug targets

21 January 2018

1 reference

Fibrotic disease and the T(H)1/T(H)2 paradigm

21 January 2018

1 reference

Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis

21 January 2018

1 reference

Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis

21 January 2018

1 reference

Th17 cells and their associated cytokines in liver diseases

21 January 2018

1 reference

The interleukin-17 pathway is involved in human alcoholic liver disease

21 January 2018

1 reference

TH17 cells in development: an updated view of their molecular identity and genetic programming

21 January 2018

1 reference

Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice

21 January 2018

1 reference

Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

21 January 2018

1 reference

Hepatoprotective effects of IL-22 on fulminant hepatic failure induced by d-galactosamine and lipopolysaccharide in mice

21 January 2018

1 reference

IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta , NF-kappaB, and AP-1 activation

21 January 2018

1 reference

IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure.

21 January 2018

1 reference

γδ T cells protect against lung fibrosis via IL-22.

21 January 2018

1 reference

Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice

21 January 2018

1 reference

The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings

21 January 2018

1 reference

Cannabinoid-based drugs as anti-inflammatory therapeutics

21 January 2018

1 reference

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

21 January 2018

1 reference

Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases

21 January 2018

1 reference

Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration

21 January 2018

1 reference

Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury

21 January 2018

1 reference

Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells

21 January 2018

1 reference

Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

21 January 2018

1 reference

Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity

21 January 2018

1 reference

Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice

21 January 2018

1 reference

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

21 January 2018

1 reference

Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5

21 January 2018

1 reference

Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent

21 January 2018

1 reference

Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation

21 January 2018

1 reference

Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B.

21 January 2018

1 reference

Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27.

21 January 2018

1 reference

The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes

21 January 2018

1 reference

The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity

21 January 2018

1 reference

Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation

21 January 2018

1 reference

Interleukin-15 increases hepatic regenerative activity

21 January 2018

1 reference

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor.

21 January 2018

1 reference

Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production

21 January 2018

1 reference

Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice

21 January 2018

1 reference

7 January 2021

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

1 reference

7 January 2021

Endocannabinoids and liver disease

1 reference

7 January 2021

The liver X receptor in hepatic stellate cells: a novel antifibrogenic target?

1 reference

7 January 2021

Negative regulators take center stage

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.26598

1 reference

24 March 2018

1 reference

24 March 2018